Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023
March 22, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 22, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, CFO and co-CEO, will present a company overview at the Virtual Investor Summit...
Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug
February 22, 2023 08:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat...
Bioxytran to Appear on ClearThink IR’s Virtual Live Event
February 14, 2023 09:00 ET
|
BIOXYTRAN, INC.
- Wednesday, February 15th, 2023 12:00 EST - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”),...
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
February 06, 2023 09:00 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19...
Vyant Bio Commences a Cash Preservation Plan Including a Reduction in Force
February 03, 2023 06:00 ET
|
Vyant Bio, Inc.
Continuing to Explore Strategic Alternatives CHERRY HILL, N.J., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company...
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements
January 25, 2023 08:30 ET
|
ANPAC BIO-MEDICAL SCIENCE CO., LTD.
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on...
Oncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer
January 25, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a clinical stage biotechnology company, with a planned IPO of...
Bioxytran Interview at the Emerging Growth Conference
January 24, 2023 14:10 ET
|
BIOXYTRAN, INC.
- Wednesday, January 25, 2023 10:50 am –11:20am EST - Discussion of the Biotech Showcase Conference BOSTON, MASSACHUSETTS, Jan. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the...
AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing
January 20, 2023 16:30 ET
|
ANPAC BIO-MEDICAL SCIENCE CO., LTD.
New York, NY, Jan. 20, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on...
Oncotelic Announces the launch of PDAO token
January 17, 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
- PDAO is to Revolutionize Decentralized Autonomous Organization (DAO) AGOURA HILLS, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the...